Dataset Information

Infiltration of CD8⁺ FOXP3⁺ T cells, CD8⁺ T cells, and FOXP3⁺ T cells in non-small cell lung cancer microenvironment.

ABSTRACT:

Background

Studies about CD8⁺ FOXP3⁺ T cells as a subtype of regulatory T cells (Treg cells) in non-small cell lung cancer (NSCLC) are few. Associations among the clinicopathologic factors of NSCLC and tumor-infiltrating lymphocytes (TILs) such as CD8⁺ FOXP3⁺ T cells, CD8⁺ T cells, FOXP3⁺ T cells and tumor PD-L1 expression are unclear.

Methods

We retrospectively enrolled 192 patients who underwent resections for NSCLC. We used tissue microarrays (TMA) with multiplex immunofluorescence and immunohistochemistry staining to evaluate the expression of CD8, FOXP3, cytokeratin, DAPI and PD-L1. We then used Wilcoxon test, Kaplan-Meier method, and Cox hazard proportion model to analyze their relationships with clinicopathologic factors and prognosis.

Results

Density of tumor CD8⁺ FOXP3⁺ T cells was significant by univariate analysis, and positively associated with tumor CD8⁺ T cells and FOXP3⁺ T cells. Density of tumor CD8⁺ T cells was higher in lung adenocarcinoma (LUAD) than squamous cell carcinoma (LUSC), and was an independent prognostic factor for NSCLC. The density of tumor FOXP3⁺ T cells decreased with tumor size. Tumor PD-L1 expression was higher in LUSC than LUAD. Cox hazard proportion model analysis correlated being younger than 65 years, early TNM stage, early T stage, high tumor CD8⁺ T cell density, and adjuvant chemotherapy with longer overall survival.

Conclusion

Infiltration of CD8⁺ FOXP3⁺ T cells, CD8⁺ T cells, and FOXP3⁺ T cells is important in non-small cell lung cancer microenvironment, and needs to be investigated more.

SUBMITTER: Hao J

PROVIDER: S-EPMC7270696 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Infiltration of CD8+ FOXP3+ T cells, CD8+ T cells, and FOXP3+ T cells in non-small cell lung cancer microenvironment.

Hao Jianqing J Wang Helin H Song Lai L Li Shuping S Che Nanying N Zhang Shucai S Zhang Hongtao H Wang Jinghui J

International journal of clinical and experimental pathology 20200501 5

<h4>Background</h4>Studies about CD8+ FOXP3+ T cells as a subtype of regulatory T cells (Treg cells) in non-small cell lung cancer (NSCLC) are few. Associations among the clinicopathologic factors of NSCLC and tumor-infiltrating lymphocytes (TILs) such as CD8+ FOXP3+ T cells, CD8+ T cells, FOXP3+ T cells and tumor PD-L1 expression are unclear.<h4>Methods</h4>We retrospectively enrolled 192 patients who underwent resections for NSC ...[more]

PMID: 32509058

Similar Datasets

Project description:PurposeThe role of RNA N6-methyladenosine (m6A) modification in the progression of multiple tumours and the tumour microenvironment (TME) has been progressively demonstrated and promises a new direction for tumour therapy. However, there have been no reports on systematic analyses of RNA m6A modification in TME in non-small cell lung cancer (NSCLC).Patients and methodsIn this study, we used unsupervised cluster analysis to identify three m6A modification patterns of 28 m6A regulators and three m6A gene signature subgroups of commonly differentially expressed genes (co-DEGs) in the three m6A modification patterns. Quantifying these subtypes using the ssGSEA and ESTIMATE algorithms to characterise the tumour immune microenvironment (TIME) in NSCLC. Based on the principal component analysis (PCA), we used co-DEGs to construct m6A scores to analyse the characteristics of m6A modifications in individual patients and assessed the practical clinical utility of m6A scores using a nomogram for survival prediction.ResultsA total of 28 m6A regulators in 1210 NSCLC samples were mainly enriched in RNA modification and metabolic biological processes. The three following m6A modification patterns were identified based on the role of the 28 m6A regulators in TME: immune inflammation, immune evasion and immune desert. The m6A scores calculated based on co-DEGs in these modification patterns were significantly positively correlated with immune infiltration and significantly negatively correlated with tumour mutational burden (TMB). Survival was significantly better in the high-m6A-score group than in the low-m6A-score group, and the m6A score could be used as an independent favourable prognostic factor. In addition, assessment of both immune checkpoint inhibitors (ICIs) and immunophenoscore (IPS) revealed a better immunotherapeutic effect in the high-m6A-score group.ConclusionThe modification characteristics of 28 m6A regulators in the TIME of NSCLC were analysed from a comprehensive to an individual basis, which may facilitate the development of more effective clinical immunotherapeutic strategies.